Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline / 부인종양
Journal of Gynecologic Oncology
; : e31-2019.
Article
Dans En
| WPRIM
| ID: wpr-740184
Responsable en Bibliothèque :
WPRO
ABSTRACT
In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Rendez-vous et plannings
/
Vaccination
/
Vaccins contre les papillomavirus
/
Corée
Type d'étude:
Guideline
Limites du sujet:
Female
/
Humans
/
Male
Pays comme sujet:
Asia
langue:
En
Texte intégral:
Journal of Gynecologic Oncology
Année:
2019
Type:
Article